40116-81-2

Basic information

• Product Name: (R)-3-morpholino-1-phenylpropan-1-ol
• Synonyms: (R)-3-morpholino-1-phenylpropan-1-ol
• CAS NO: 40116-81-2
• Molecular Weight: 221.299
• Mol File: 40116-81-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-3-morpholino-1-phenylpropan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-morpholino-1-phenylpropan-1-ol(40116-81-2)
• EPA Substance Registry System: (R)-3-morpholino-1-phenylpropan-1-ol(40116-81-2)

Safety Data

• Hazardous Substances Data: 40116-81-2(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 110-91-8 morpholine 
• 4393-06-0 1-Phenyl-2-propen-1-ol 
• 100306-33-0 (1R)-3-chloro-1-phenylpropanol 
• 2298-48-8 3-morpholin-4-yl-1-phenyl-propan-1-one 

Relevant articles and documents

Asymmetric Synthesis of γ-Secondary Amino Alcohols via a Borrowing-Hydrogen Cascade

The borrowing-hydrogen (or hydrogen autotransfer) process, where the catalyst dehydrogenates a substrate and formally transfers the H atom to an unsaturated intermediate, is an atom-efficient and environmentally benign transformation. Described here is an example of an asymmetric borrowing-hydrogen cascade for the formal anti-Markovnikov hydroamination of allyl alcohols to synthesize optically enriched γ-secondary amino alcohols. By exploiting the Ru-(S)-iPrPyme catalyst with minimal stereogenicity, a cascade process including dehydrogenation, conjugate addition, and asymmetric reduction was developed. The mild conditions, functional group tolerance, and broad substrate scope (54 examples) demonstrate the synthetic practicality of the catalytic system.

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.